Key Segmentation:
By Vaccine Type
-
Conjugate (TCV)
-
Vi Polysaccharide (Vi-PS)
-
Live Attenuated Ty21a
-
Other Vaccine Types
By Route of Administration
-
Injectable
-
Oral
By Age Group
-
6 Months to Less Than 2 Years
-
2 to 5 Years
-
6 to 15 Years
-
More Than 15 Years
By End User
-
Public Health & Government Programs
-
Hospitals & Clinics
-
Travel & Retail Clinics and Pharmacies
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Vaccine Type X Age Group)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Key players include Bharat Biotech International Limited, Biological E. Limited, Sanofi S.A. and PT Bio Farma (Persero), among others.
Key opportunities include bivalent typhoid-paratyphoid vaccines, regional manufacturing in Africa and South Asia, and thermostable formulations for remote settings.
The primary growth factor is the WHO and Gavi-backed rollout of typhoid conjugate vaccines, combined with rising drug-resistant typhoid in South Asia and Africa.
By vaccine type, the Vi Polysaccharide segment dominates the Typhoid Fever Vaccines Market with approximately 41.86% share in 2025.
Asia-Pacific dominates the Typhoid Fever Vaccines Market, while North America accounts for approximately 12.84% share in 2025.
